Alzheimer disease trials in United Kingdom

In United Kingdom 41 Also abroad 816

41 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 2/3Taking people
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
Where
Aberdeen, Edinburgh
Age
55 years to 90 years
People
300 worldwide
Run by
Exciva GmbH
See details and how to joinNCT07284472 · EU 2024-517388-22-00
Phase 2Taking people
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
Where
Bath, London
Age
55 years to 85 years
People
160 worldwide
Run by
Sanofi
See details and how to joinNCT07688213 · EU 2025-524581-14-00
Phase 3Taking people
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Where
Aberdeen, Birmingham, Chertsey, Edinburgh, London, Southampton
Age
55 years to 80 years
People
1,600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07717411
Phase 3Taking people
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Where
Cambridge, Chertsey, London, Motherwell, Preston, Redruth, Sheffield, Stafford, Wolverhampton
Age
55 years to 90 years
People
426 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07011745 · EU 2025-520612-34-00
Phase 1Taking people
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
Where
London, Sheffield, Southampton
Age
50 years to 85 years
People
56 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06297590 · EU 2024-510604-37-00
Phase 1Taking people
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
Where
Huntley Street, Sheffield
Age
18 years and over
People
60 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT05231785 · EU 2023-508363-79-00
Phase 2Taking people
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Where
Aberdeen, Bath, Birmingham, Edinburgh, London, Oxford, Southampton
Age
50 years to 85 years
People
340 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07033494 · EU 2024-519190-19-00
Phase 3Taking people
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Where
Aberdeen, Chertsey, Ilford, Leeds, Motherwell, Preston, Sheffield, SouthYorkshire, Swindon, Swinton
Age
55 years to 90 years
People
1,000 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00
Phase 3Taking people
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Where
Aberdeen, Chertsey, Edinburgh, Ilford, Leeds, London, Motherwell, Preston, Sheffield, SouthYorkshire, Swinton
Age
55 years to 90 years
People
500 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06126224 · EU 2023-504416-16-00
Phase 3Taking people
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Where
Cambridge, Chertsey, London, Motherwell, Preston, Redruth, Sheffield, Stafford, Wolverhampton
Age
55 years to 90 years
People
650 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Where
Birmingham, Edinburgh, Leeds, London, Manchester, Motherwell, Oxford, Sheffield
Age
60 years to 85 years
People
586 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06976203 · EU 2025-520747-32-00
Phase 1Taking people
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
Where
Glasgow, London, Sheffield, Southampton
Age
40 years to 80 years
People
50 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07214727 · EU 2025-522582-30-00
No phaseTaking people
Dominantly Inherited Alzheimer Network (DIAN)
Where
London
Age
18 years and over
People
700 worldwide
Run by
Washington University School of Medicine
See details and how to joinNCT00869817
No phaseTaking people
The Role of METhanogens in the PROgression Of Parkinson's Disease and Related Neurological Conditions
Where
Cambridge
Age
55 years and over
People
215
Run by
University of Cambridge
See details and how to joinNCT07786116
No phaseNot yet taking people in United Kingdom
A Postmarketing Study of LEQEMBI in United Kingdom (UK) Participants With Alzheimer's Disease (AD)
Where
Edinburgh, London, Motherwell
People
400
Run by
Eisai Limited
See details and how to joinNCT07781345
Phase 1Taking people
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease
Where
Manchester
Age
18 years to 75 years
People
178
Run by
Denali Therapeutics Inc.
See details and how to joinNCT07758595
Phase 3Taking people
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Where
Aberdeen, Motherwell, Swindon
Age
55 years to 90 years
People
410 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05511363
No phaseTaking people
Lived Experience Narratives in Dementia
Where
Nottingham
Age
18 years to 99 years
People
60
Run by
University of Nottingham
See details and how to joinNCT07757178
Phase 2/3Taking people
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Where
London
Age
18 years and over
People
280 worldwide
Run by
Washington University School of Medicine
See details and how to joinNCT05552157
Phase 2/3Taking people
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Where
London
Age
18 years and over
People
280 worldwide
Run by
Washington University School of Medicine
See details and how to joinNCT06647498
Phase 3Taking people
An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's Disease
Where
Cambridge, Chertsey
Age
55 years and over
People
1,200
Run by
University College, London
See details and how to joinNCT07724132
Phase 1/2Taking people
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
Where
Cambridge, Liverpool, London, Oxford, Warrington
Age
35 years to 85 years
People
304 worldwide
Run by
AC Immune SA
See details and how to joinNCT05462106 · EU 2022-500069-29-00
Phase 1Taking people
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
Where
London
Age
18 years to 75 years
People
68 worldwide
Run by
Denali Therapeutics Inc.
See details and how to joinNCT07328451 · EU 2025-523515-11-00
Phase 3Taking people
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
Where
Chertsey, Crowborough, Exeter, London, Motherwell, Oxford, Sheffield
Age
55 years to 90 years
People
325 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06947941
No phaseTaking people
The Co-Production and Evaluation of the Computerised Cognitive Assessment for Preclinical Alzheimer's Disease (CoCoA-PAD)
Where
Exeter, London, Plymouth
Age
65 years and over
People
120
Run by
University of Plymouth
See details and how to joinNCT07598617